Search
forLearn
5 / 801 resultslearn HT-B
learn Follistatin
glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin
learn glutamic acid
learn PTD-DBM
Research
5 / 1000+ resultsresearch Does maternal exposure to artificial food coloring additives increase oxidative stress in the skin of rats?
Maternal exposure to artificial food coloring may increase skin disease risk in rat offspring.
research Glutathione S-transferase gene polymorphism, total antioxidant status, and blood pressure changes in androgenic alopecia
Gene variations may increase oxidative stress in male pattern baldness.
research Impact of the Different Preparation Methods to Obtain Autologous Non-Activated Platelet-Rich Plasma (A-PRP) and Activated Platelet-Rich Plasma (AA-PRP) in Plastic Surgery: Wound Healing and Hair Regrowth Evaluation
Different methods of preparing Platelet-Rich Plasma (PRP) can affect wound healing and hair regrowth in plastic surgery. Using a kit with specific standards helps isolate PRP that meets quality criteria. Non-Activated PRP and Activated PRP have varying effects depending on the tissue and condition treated. For hair regrowth, Non-Activated PRP increased hair density more than Activated PRP. Both treatments improved various aspects of scalp health.
research Hair Loss in Patients with Inflammatory Bowel Disease
People with Inflammatory Bowel Disease often lose hair due to stress, medication side effects, or lack of nutrients, and treatment depends on the specific cause.
research White Lupin Cluster Root Acclimation to Phosphorus Deficiency and Root Hair Development Involve Unique Glycerophosphodiester Phosphodiesterases
White lupin uses specific genes to grow root hairs and access phosphorus when it's scarce.
Community Join
5 / 1000+ resultscommunity Where is GT20029 already? Grrrr
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community GT20029 - Stand-alone Saviour or just part of the stack?
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
community bro where tf is GT20029, Q1 2024 is over already
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.